Pfizer on Tuesday said that the pharmaceutical company seeks approval for emergency use authorization to administer its vaccine to children in September. The goal is to immunize the age group between 2 and 11. The company disclosed its desire during an earnings call on Tuesday.
It is aiming for a plan to extend the emergency use authorization for further administering doses in 16 to 85-year-olds. For that matter, the company is filing an approval request from the Food and Drug Administration. Pfizer is genuinely putting discern endeavor to alleviate the American’s concerns and vaccine hesitancy.
“The Pfizer-BioNTech pediatric study evaluating the safety and efficacy of our COVID-19 vaccine in children six months to 11 years of age is ongoing,” the company said in prepared remarks before an earnings call with investors Tuesday. “We expect to have definitive readouts and submit for an [emergency use authorization] for two cohorts, including children 2-5 years of age and 5-11 years of age, in September.”
The New York Times published a study last week indicating the stance on the FDA approval to the drugmaker. If the drugmaker gains further progress in the proposal, then it will be allowed to market the vaccines directly to the consumers. The vaccination drive has been a profitable avenue for the state as well as the pharmaceutical company as both of them benefitted from the virulence of Covid-19 infections.